미국의 항진균제 시장 규모, 점유율, 동향 분석 보고서 : 약제 클래스별, 적응증별, 제형별, 유통 채널별, 부문별 예측(2025-2030년)

U.S. Antifungal Drugs Market Summary

The U.S. antifungal drugs market was estimated at USD 6.05 billion in 2024 and is projected to reach USD 7.20 billion by 2030, growing at a CAGR of 3.0% from 2025 to 2030. The growing incidence of fungal infections drives market expansion.

Fungal infections cover a broad range of conditions, from athlete's foot, ringworm, and vaginal yeast infections to severe systemic diseases such as candidemia, aspergillosis, and mucormycosis. The CDC identifies Candida auris and resistant Aspergillus species as serious threats, necessitating therapeutic advances and enhanced infection control. The U.S. antifungal drugs industry is mainly driven by a consistent increase in fungal infections among immunocompromised groups, such as cancer patients, transplant recipients, and individuals with HIV; a rise in ICU admissions; and the increased use of medical devices such as catheters and ventilators. This population is particularly vulnerable to invasive infections such as candidemia and aspergillosis, which require systemic antifungal treatments. Furthermore, superficial fungal infections such as onychomycosis and dermatophytosis remain widespread and frequently recur, maintaining steady demand for oral and topical antifungal medications. Surveillance data show that non-albicans Candida species cause approximately two-thirds of bloodstream infections, with 6% of isolates resistant to fluconazole and 2% of C. glabrata isolates resistant to echinocandins, highlighting the need for newer and more effective antifungal therapies.

Systemic fungal infections continue to pose a significant healthcare challenge in the U.S. Each year, more than 75,000 hospitalizations and nearly 9 million outpatient visits are attributed to fungal diseases, as per the CDC in May 2024. As per April 2024 data, ab out 25,000 cases of candidemia occur annually, with roughly one-third of patients dying during their hospital stay. Public health initiatives are steadily raising awareness of fungal diseases. The CDC's Fungal Disease Awareness Week, scheduled for September 2025, aims to promote early diagnosis and enhance resistance surveillance.

U.S. Antifungal Drugs Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the U.S. antifungal drugs market on the basis of drug class, indication, dosage form, and distribution channel:

• Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)
• Azoles
• Echinocandins
• Polyenes
• Allylamines
• Others
• Indication Outlook (Revenue, USD Billion, 2018 - 2030)
• Dermatophytosis
• Aspergillosis
• Candidiasis
• Others
• Dosage Form Outlook (Revenue, USD Billion, 2018 - 2030)
• Oral Drugs
• Ointments
• Powders
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
• Hospital Pharmacies
• Retails Pharmacies
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug class
  • 1.2.2. Indication
  • 1.2.3. Dosage form
  • 1.2.4. Distribution channel
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug class outlook
  • 2.2.2. Indication outlook
  • 2.2.3. Dosage form
  • 2.2.4. Distribution channel
• 2.3. Competitive Insights

Chapter 3. U.S. Antifungal Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Antifungal Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. U.S. Antifungal Drugs Market: Pipeline Analysis

Chapter 4. U.S. Antifungal Drugs Market: Drug class Estimates & Trend Analysis

• 4.1. Drug Class Segment Dashboard
• 4.2. U.S. Antifungal Drugs Market: Drug Class Movement Analysis
• 4.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. Azoles
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Echinocandins
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.6. Polyenes
  • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.7. Allylamines
  • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Antifungal Drugs Market: Indication Estimates & Trend Analysis

• 5.1. Indication Segment Dashboard
• 5.2. U.S. Antifungal Drugs Market: Indication Movement Analysis
• 5.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Billion)
• 5.4. Dermatophytosis
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Aspergillosis
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Candidiasis
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Antifungal Drugs Market: Dosage Form Estimates & Trend Analysis

• 6.1. Dosage Form Segment Dashboard
• 6.2. U.S. Antifungal Drugs Market: Dosage Form Movement Analysis
• 6.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Dosage Form, 2018 to 2030 (USD Billion)
• 6.4. Oral Drugs
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Ointments
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Powders
  • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Antifungal Drugs Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Distribution Channel Segment Dashboard
• 7.2. U.S. Antifungal Distribution Channel: Indication Movement Analysis
• 7.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Billion)
• 7.4. Hospital Pharmacies
  • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.5. Retails Pharmacies
  • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Novartis Pharmaceuticals Corporation
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Pfizer Inc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Bayer AG
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Sanofi.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Merck & Co., Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. GSK plc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Abbott.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. GLENMARK PHARMACEUTICALS INC., USA
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Enzon Pharmaceuticals, Inc.
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Astellas Pharma US, Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives